Nuclear Pharmacy

Nuclear Pharmacy Specialty Certification (BCNP)

Target Population: Pharmacists who specialize in the procurement, preparation, compounding, dispensing, and distribution of radiopharmaceuticals, as well as the regulatory aspects governing these processes.

Program Purpose: To validate that the pharmacist has the advanced knowledge and experience to improve patient outcomes and public health through the safe and effective use of radioactive drugs for diagnosis and therapy.

Currently there are more than 350 BPS Board-Certified Nuclear Pharmacists.

Nuclear Pharmacy Specialty Council Members

The purpose of the BPS Specialty Councils is to develop standards and eligibility requirements for board certification, develop examinations and passing standards for certification, and review and approve professional development programs for recertification of board-certified pharmacists. Specialty council members are at the heart of the peer-reviewed and peer-developed nature of BPS Board Certification.

Leana Gebo, Chair PharmD, BCNP

Gebo is the nuclear pharmacy manager for Cardinal Health Nuclear & Precision Health Solutions in Beltsville, MD overseeing operations at the 70+ employee radiopharmacy which services the Washington, DC/Baltimore, MD metro markets and beyond. During her career as a nuclear pharmacist since 2007, Gebo has served as a staff nuclear pharmacist, radiation safety officer, certified Kaizen Leader, and pharmacist in charge. She enjoys overseeing clinical trial programs for both low and high energy products, seeing novel radiopharmaceuticals come to market, and striving to provide excellent service to her customers and patients. Gebo received her PharmD from Nova Southeastern University in Fort Lauderdale, FL.

Nic Mastascusa, Vice Chair PharmD, RPh, BCNP

Mastascusa is the Chief Nuclear Pharmacist at The University of Iowa Hospitals & Clinics and Clinical Assistant Professor at the University of Iowa College of Pharmacy. He earned his pharmacy degree at the University of Iowa, completed authorized nuclear pharmacist training through Purdue University in 2008 and became board certified in 2017. He oversees the daily clinical functions of the radiopharmacy and thoroughly enjoys teaching pharmacy students, radiology residents and nuclear medicine technology students. Mastascusa is active in multiple organizations including APhA and SNMMI. He has had several roles in his career including pharmacy manager, radiation safety officer and customer services and education coordinator for a commercial radiopharmacy.

Andrew Brown, PharmD, RPh, BCNP

Brown currently practices as the Quality Assurance Manager for Cardinal Health Nuclear & Precision Health Solutions Quality & Regulatory Pharmacy Practice Group. In this role he focuses on patient safety, clinical nuclear pharmacy, and regulatory compliance. Prior to his current role, he provided direct patient care as a Specialty Practice Pharmacist (Nuclear) at the OSU Wexner Medical Center/James Cancer Hospital. Brown also practiced pharmacy in a variety of fields including as centralized nuclear pharmacy, sterile compounding, and hospital-based clinical pharmacy. Brown graduated from Ohio Northern University’s Raabe College of Pharmacy with a Doctor of Pharmacy degree in 2005. He completed his Authorized Nuclear Pharmacist training in 2009 and achieved Board Certified Nuclear Pharmacist status in 2011.

Jeff Clanton, DPh, MS, BCNP

Dr. Clanton has been a leader and supporter of the nuclear pharmacy and nuclear medicine professions for over 40 years where he had the opportunity to develop vast firsthand experience with single photon, positron emitting and therapeutic radiopharmaceuticals. Experience that includes research (INDs), regulatory (NRC, USP, cGMP and pharmacy law) as well as operations. During his 38 plus year career at Vanderbilt University Medical Center, he was Director of Radiopharmacy Services, Manager of the Cyclotron Facility and a member of the Medical School Faculty where he was responsible for production, operation and delivery of prepared radiopharmaceuticals to the patient. Additionally, his job entailed teaching, research, regulatory compliance, procurement, and budgets. Dr. Clanton co-authored and maintained three Investigational New Drug applications {INDs), authored or co-authored 90+ peer-reviewed scientific papers and 100+ abstracts for presentation at national meetings. He was a long-standing member of the Pharmacy and Therapeutics committee, Human Subjects Radiation Committee, Radiation Safety Committee, and Chairman of Radioactive Drug Research Committee. Dr. Clanton co-founded and co-owned an independent, commercial radiopharmacy and was responsible for operations and regulatory compliance. In addition, as a consultant for PETNet Pharmaceutical Services, he was responsible for the placement, build out, training, compliance and startup of three PET cyclotron manufacturing facilities with pharmacies in Kentucky, Arkansas and Louisiana He is active in the American Pharmacists Association (APhA) serving as a past national delegate (Section on Pharmacy Specialties). His service with the Society of Nuclear Medicine and Molecular Imaging (SNMMI) included acting as President of the Radiopharmaceutical Sciences Council. He served on multiple committees within the Board of Pharmaceutical Specialties (BPS) having been in the first group of pharmacists certified in 1982 (BCNP) and on several committees for the United States Pharmacopeia (USP). He is the 2020 recipient of the William H. Briner Distinguished Achievement Award in Nuclear Pharmacy Practice to be presented at APhA’s annual meeting. He is currently an Independent Radiopharmacy Consultant, based in Nashville, Tennessee. He enjoys assisting his clients develop a better understanding regarding radiopharmaceutical sciences and compliance.

Ronald J. Crowe, RPh, BCNP

Crowe is the Managing Director of the Emory University Center for Systems Imaging Radiopharmacy Core in Atlanta, Georgia. He has been practicing Nuclear Pharmacy since graduating from the University of Georgia College of Pharmacy in 1990. Crowe obtained his BCNP designation in 1993. He has been managing the PET Radiopharmacy at Emory since 1997 and works primarily with human research PET radiopharmaceuticals under RDRC oversite but also translates new radiopharmaceuticals from “benchtop to bedside” through the submission of FDA Investigational New Drug applications.

Akram Hussein, PharmD, MBA, BCNP

Akram Hussein is the Director of Nuclear Medicine Radiopharmacy at The University of Texas MD Anderson Cancer Center. Akram brings many years of radiopharmaceutical and operations experience spanning both commercial and hospital nuclear pharmacy settings. Akram’s previous roles included serving as the administrator and manager of the nuclear pharmacy at the Ohio State University Wexner Medical Center and James Cancer Hospital and Solove Research Institute, and as a lead nuclear pharmacist at Cardinal Health. Akram has previously served as APhA-APPM Nuclear Pharmacy Practice SIG Coordinator and Chair of the Nuclear Pharmacy Education Committee for the American Pharmacist Association. He is also a member of the Society of Nuclear Medicine & Molecular Imaging. Akram earned his Doctor of Pharmacy degree from the University of Findlay College of Pharmacy and his Master of Business Administration from Franklin University. Akram received his board certification in nuclear pharmacy from the Board of Pharmacy Specialties in 2016.

Paul Knapp, RPh, MBA, BCNP

Knapp is a graduate of The University of Pittsburgh School of Pharmacy, and has been a nuclear pharmacist since graduating in 1995. He has been Board Certified since 1998, and earned an MBA from Franklin University in 2008. After staffing, managing, and serving as RSO at several Cardinal Health radiopharmacies, Knapp joined their Quality & Regulatory Department in 2006 where he now manages programs dealing with clinical trial services, R&D, new product launches, patient privacy, government and industry relations, and general radiopharmaceutical practice and clinical support. He is active in several professional and industry organizations, including APhA, CORAR, and BPS.

Steve Mattmuller, MS, RPh, BCNP

Mattmuller is the Chief Nuclear Pharmacist at Kettering Medical Center in Kettering, OH. He received his BSPh from the Ohio Northern University and his MSRPh from the University of Southern California. He currently oversees all operations involving the preparation of SPECT radiopharmaceuticals and the production of PET radiopharmaceuticals. Mattmuller has been active with APhA and the SNMMI as well as serving on the NRC ACMUI committee.

Eric Smith, PharmD, MS, BCNP, FAPhA

Smith is a Senior Expert in the Targeted Alpha Therapy team at Bayer Pharmaceuticals. He also holds an appointment as Professor of Pharmacy at University of North Carolina’s Eshelman School of Pharmacy. He received a bachelor’s degree in chemistry from Cedarville University, and then earned his master’s and Doctor of Pharmacy degrees from Purdue University.

Kristin Watson Swann, PharmD, MS, BCNP

Swann is a nuclear pharmacist with Cardinal Health Nuclear & Precision Health Solutions in Memphis, TN. She is a Lean Six Sigma Specialist, Environmental Health & Safety Lead, and Preceptor for summer interns & APPE students. In addition, she serves as a Clinical Assistant Professor for UAMS College of Pharmacy in Little Rock, AR, teaching both pharmacy and nuclear medicine technician students. Swann enjoys sharing her passion for radiopharmacy through both hands-on training and teaching opportunities. She received her Masters in Physics from the University of Chicago and her PharmD from UAMS. She currently holds six state licenses across the southern region.

Shunsuke Toyoda, PharmD, BCPS, BCNSP, BCSCP, CPHQ

Dr.Toyoda obtained Bachelor’s Degree in Chemistry from Occidental College, and Doctor of Pharmacy from University of California- San Francisco School of Pharmacy. Dr.Toyoda works at PIH Health Hospital-Whittier in Los Angeles, California, as a sterile compounding pharmacist. He ensures that sterile products for the hospital is compounded in accordance to USP 797 standards. As a PGY1 preceptor, he also teaches inpatient sterile compounding procedure. Dr.Toyoda volunteers his time to continuing education sessions for Japan and the US on sterile compounding topics.

Eligibility Requirements

An applicant for board certification in Nuclear Pharmacy must demonstrate all of the eligibility requirements listed below. For examinations in the windowed testing format, all practice and education eligibility requirements must be met prior to sitting for the initial certification examination. For examinations in the continuous testing format, all practice and education eligibility requirements must be met before submitting the application. Once all of the requirements below are met, an applicant will be deemed eligible to sit for the Nuclear Pharmacy specialty certification examination. If an applicant achieves a passing score on the Nuclear Pharmacy specialty certification examination, they may use the designation Board-Certified Nuclear Pharmacist, or BCNP.

  • Graduation from a pharmacy program accredited by the Accreditation Council for Pharmacy Education (ACPE) or a program outside the U.S. that qualifies the individual to practice in the jurisdiction.
  • A current, active license/registration to practice pharmacy in the U.S. or another jurisdiction.
  • Demonstration of practice experience through 4,000 hours of practice experience after licensure/registration as a pharmacist1 in nuclear pharmacy. The 4,000 hours may be earned in a variety of settings, but must be from within the past seven years prior to application date:
    • Completion of training/experience required for an authorized nuclear pharmacist as identified by the United States Nuclear Regulatory Commission (NRC) Regulations (10 CFR) § 35.55 Training for an authorized nuclear pharmacist. This option is limited to pharmacists who have graduated from a pharmacy program accredited by the American Council on Pharmaceutical Education (ACPE) or have passed the Foreign Pharmacy Graduate Examination Committee (FPGEC) examination. Supporting documentation to satisfy completion of training/experience required for an authorized nuclear pharmacist is a current, active radioactive material program (RAM) license issued by the NRC or a state with NRC Agreement State status.
    • Successful completion of PGY12 or PGY2 Nuclear Pharmacy residency within the past seven years, hour-for-hour credit to a maximum of 2,000 hours.
    • Internship to satisfy requirements of state boards of pharmacy: hour-for-hour credit in a licensed nuclear pharmacy or facility authorized to handle radioactive materials, to a maximum of 2,000 hours1.
    • Nuclear Pharmacy practice: hour-for-hour credit in a licensed nuclear pharmacy or health care facility approved by state or federal agencies to handle radioactive materials, to a maximum of 4,000 hours.

1All practice experience must be completed post-licensure/registration as a pharmacist. All applicants intending to demonstrate eligibility for any BPS certification examination utilizing the practice experience pathway must provide an attestation from their employer, on company letterhead, that verifies this experience accurately represents at least 50% of time spent in some or all of the activities defined by the applicable certification content outline. In addition, this practice experience must have occurred within the seven years immediately preceding the application. For more information, click here. A sample employer verification letter is available here.

2American Society of Health-System Pharmacists (ASHP)-accredited/candidate status PGY1 pharmacy residency, residencies accredited under the ASHP Accreditation Standard for International Pharmacy Practice Residency Programs, or Canadian Pharmacy Residency Board (CPRB)-accredited Year 1 pharmacy residency.

The rationale for the appropriateness of the requirements for BPS certification programs are based upon the following:

  • BPS recognizes individuals who graduate from a recognized school or college of pharmacy within the candidate’s jurisdiction. Those jurisdictions recognize and evaluate programs on the extent to which it accomplishes its stated goals and is consistent with the concept that pharmacy is a unique, personal service profession in the health science field. In the United States, the responsibility for recognizing schools and colleges of pharmacy falls to the Accreditation Council for Pharmacy Education (ACPE).
  • The rationale for requiring licensure or registration of pharmacists within their jurisdiction is based upon the fact that for public protection, all pharmacists must be licensed or registered. This is considered a baseline requirement to be a pharmacist specialist. In the United States, BPS recognizes the licensure process administered by the National Association of Boards of Pharmacy (NABP). The National Association of Boards of Pharmacy (NABP) aims to ensure the public’s health and safety through its pharmacist license transfer and pharmacist competence assessment programs. NABP’s member boards of pharmacy are grouped into eight districts that include all 50 United States, the District of Columbia, Guam, Puerto Rico, the Virgin Islands, Bahamas, and all 10 Canadian provinces.
  • The experiential component is required to help assure practical application of components of the specialty knowledge being certified. There are multiple pathways to meet the practice experience requirement. The faster eligibility pathways recognize accredited residencies through the American Society of Health System Pharmacists (ASHP). The ASHP residency accreditation program identifies and grants public recognition to practice sites having pharmacy residency training programs that have been evaluated and found to meet the qualifications of one of the ASHP’s residency accreditations standards. Thus, accreditation of a pharmacy residency program provides a means of assurance to residency applicants that a program meets certain basic requirements and is, therefore, an acceptable site for postgraduate training in pharmacy practice in organized health care.
  • Passing the BPS pharmacy specialty examination helps assure knowledge consistent with the validated content outline for the BPS specialty.

The appropriateness of the BPS program requirements are consistent with the Council on Credentialing in Pharmacy’s Resource Paper titled: Scope of Contemporary Pharmacy Practice: Roles, Responsibilities, and Functions of Pharmacists and Pharmacy Technicians.

Upcoming Deadlines

Individuals who meet the eligibility requirements for the BCNP examination can find more information about examination dates and fees for certification examinations here

Candidate's Guide

The Candidate’s Guide is intended for use by pharmacists who are interested in becoming certified as specialists by BPS in any of the BPS-recognized specialty practice areas. To review critical information for BPS Certification Examinations, visit this page.

Content Outline for BCNP

For the 2024 Examinations and forward, refer to the Nuclear Pharmacy Content Outline found here for details.

Please note that the Nuclear Pharmacy Specialty Certification and Recertification examinations transitioned to continuous testing starting in 2023. To learn more about the transition to continuous testing, click here

The examination content outline is a product of a job analysis, also known as a role delineation study, that includes discussions with a panel of 15-20 subject matter experts who represent the specialty area. These experts determine the competencies required for safe and effective pharmacy practice in the specialty area and engage board-certified pharmacists through a validation survey for their endorsement of the identified competencies. The job analysis process is conducted every 5 years to help ensure that the competencies in the examination content outline reflect current pharmacy practice in the specialty area.

Click here to review the BCNP Job Analysis Summary.

Important Resources

Preparatory Courses for BCNP Examinations

Certification is a significant differentiator, and the rigorous exam process requires concentrated study. Successful candidates are well prepared, and a number of available resources can assist pre-qualified applicants.

Suggested preparation for the examination might include:

  • The study of journal articles, textbooks or other publications related to the Content Outline.
  • Attendance at continuing education programs and courses in specialized pharmacy practice.
  • Participation in study groups and examination preparation courses.
  • Reviewing the sample examination items provided in order for candidates to familiarize themselves with the various item formats which are presented on the exam. Sample question performance should not be interpreted as an indicator of exam performance.

To maintain its strict, independent standards for certification, BPS does NOT provide review information, preparatory courses, or study guides. However, such materials are available from outside organizations, state or local professional associations and colleges of pharmacy. Potential applicants may contact the professional associations noted below for additional study resources.

The Board of Pharmacy Specialties provides the following program listing for informational purposes. This list is not an exhaustive list of options available for examination preparation. BPS does not endorse or provide preparatory courses for Board Certification Examinations.

Nuclear Pharmacy

BPS partners with Prometric to provide the examination. BPS does not have any other partnerships for the certification or recertification application process. BPS partners with professional development program (PDP) providers to provide continuing education (CE) for recertification and the relationship is noted here. Any organization claiming a relationship with BPS for the application process or providing CE labeled ‘BPS-approved’ outside of the organizations listed should be reported to BPS immediately.

Certification for Applicants Outside the U.S.

BPS would like to offer some helpful tips to candidates outside of the United States in order to make their application experience easier. To learn more about applying for board certification as a pharmacist outside of the U.S., visit this page.

Apply for ADA Accomodations 

BPS complies with the relevant provisions of the Americans with Disabilities Act (ADA). For applicants looking to request special accommodations in their application process, more instructions can be found on this page.

Frequently Asked Questions

After review of the BPS Candidates Guide and specialty certification page, some applicants may still have questions. Visit this page to see frequently asked questions from pharmacists pursuing board certification like you!

Sample Examination Items

Sample Items for BCNP Examinations

The sample examination items for BCNP examinations are made available by BPS for the purposes of familiarizing certification candidates and other stakeholders with the structure and format of BPS Certification Examinations. This is not meant for use as a self-assessment. Performance on any of these items does not correlate with performance on the actual examination.

The content of these examples is meant to be illustrative of actual examination items, but these items do not appear on the certification examination and are not meant to identify the scope of the examination. For a more comprehensive indication of the scope of the certification examination, please refer to the BCNP Exam Content Outline.

Examination items are in multiple-choice format. The great majority of examination items are multiple-choice with a single response from among four options. Some examinations may include a small percentage of items that require selection of multiple (three or four) responses from among a larger set of available (up to eight) options. Examinations items may also be supplemented by an image.

View the examination items down below.

What is the primary radionuclidic impurity in yttrium Y–90?

Indium In–113
Strontium Sr–89
Strontium Sr–90
Thallium Tl–203

Correct!

Incorrect!

Which reagent kits is light-sensitive?

Mertiatide
Exametazime
Sestamibi
Medronate

Correct!

Incorrect!

What is an appropriate therapy for Graves disease?

10 - 15 mCi sodium iodide I-123
5 - 10 mCi sodium iodide I-131
0.5 - 1.0 mCi iodine I-131 iobenguane sulfate
75 - 150 mCi sodium iodide I-131

Correct!

Incorrect!

Dosage of yttrium Y-90 ibritumomab tiuxetan is based on:

body weight and platelet count.
body weight, platelet count, and sensitivity to murine proteins.
platelet count and biodistribution of iodine I–125 ibritumomab tiuxetan.
body surface area.

Correct!

Incorrect!

For which one of the following technetium-labeled radiopharmaceuticals may the biological distribution be altered by the presence of excessive concentrations of aluminum ion?

Pentetate
Gluceptate
Macroaggregated albumin
Sulfur colloid

Correct!

Incorrect!

If a technetium Tc-99m albumin aggregated kit containing 4 million particles was reconstituted at 6:00 AM using 50 mCi of technetium Tc-99m sodium pertechnetate, what is the earliest time at which a 4-mCi dosage would include more particles than the recommended limit of 700,000?

9:00 AM
11:00 AM
1:00 PM
3:00 PM

Correct!

Incorrect!

Which represents the activity of 20 mCi?

7.4 MBq
74 MBq
740 MBq
7.4 GBq

Correct!

Incorrect!

According to the USP, what is the maximum allowable aluminum-ion concentration in technetium Tc-99m pertechnetate solution prepared from molybdenum Mo-99 generators?

10 µg/mL
10 mg/mL
10 µg/mCi
10 mg/mCi

Correct!

Incorrect!

What is the regulatory maximum limit for Mo-99 breakthrough in any generator elution at time of administration?

1.5 µCi Mo-99 / mCi of Tc-99m
0.15 mCi Mo-99 / mCi of Tc-99m
0.15 µCi Mo-99 / mCi of Tc-99m
5 µCi per dose of Tc-99m

Correct!

Incorrect!

At what distance in centimeters would a source read 2 mR/hr if at 2 cm the radiation intensity is 500 mR/hr?
22.3
31.6
44.7
125.0

Correct!

Incorrect!

The gross mass of a radioactive package must be durably marked if it weighs more than:

55 lbs.
110 lbs.
155 lbs.
200 lbs.

Correct!

Incorrect!

What is the most likely cause of focal radioactivity in the lungs following administration of radiolabeled white blood cells?

Introduction of product through an existing central venous hyperalimentation line
Withdrawal of blood into the syringe prior to the injection
Normal distribution of the labeled leukocytes
Reinjection of cellular clumps

Correct!

Incorrect!

The use of technetium Tc-99m albumin aggregated injection is contraindicated in patients with:
shunt imaging.
severe pulmonary hypertension.
chronic obstructive pulmonary disease.
one lung.

Correct!

Incorrect!

The dosage of technetium Tc-99m disofenin given to a patient with an elevated total serum bilirubin level should be:
the same as for a patient with a normal serum bilirubin.
higher than the dosage given to a patient with a normal serum bilirubin.
contraindicated in patients with an elevated bilirubin level.
lower than the dosage given to a patient with a normal serum bilirubin.

Correct!

Incorrect!

What is the most critical time for precautions for urinary contamination after strontium chloride Sr-89 administration?
First 2 days
First week
First month
First 3 months

Correct!

Incorrect!

Share the quiz to show your results !

Subscribe to see your results

Nuclear Pharmacy Sample Questions

I got %%score%% of %%total%% right

%%description%%

%%description%%

Loading...

Recertification Requirements for BCNP

Pharmacists who earn the designation Board-Certified Nuclear Pharmacist® (BCNP) are required to maintain their certification over a seven–year period by completing one of the following recertification pathways: 

Option One: Recertification Examination

  • For BCNP with certification beginning January 1, 2023 or earlier: Achieve a passing score on the recertification examination administered by BPS.
  • For BCNP with certification beginning January 1, 2024 or later: Achieve a passing score on the recertification examination administered by BPS and self-report 20 completed units of continuing professional development (CPD) in MyBPS. For more information on CPD, review the FAQ. To maintain an active certification in good standing, a minimum of two units of BPS-approved, assessed CPE or self-reported CPD must be reported each year.

OR

Option Two: Professional Development Program

  • For BCNP with certification beginning January 1, 2023 or earlier: recertification via professional development program requires 100 units of assessed CPE from BPS-approved professional development programs provided by:
  • For BCNP with certification beginning January 1, 2024 or later: recertification via professional development program requires 100 units, comprised of 80 units of assessed CPE from BPS-approved professional development programs provided by:
    • Purdue University College of Pharmacy.
    • Additionally, 20 units of continuing professional development (CPD) must be completed and self-reported in MyBPS. For more information on CPD, review the FAQ. To maintain an active certification in good standing, a minimum of two units of assessed CPE from BPS-approved professional development programs or self-reported CPD must be reported each year.

 

Year certified/recertified

New cycle start

(begin earning recert units)

Cycle expiration

(deadline to meet recert reqs)

Units required 

(PDP = professional development program)

20161/1/201712/31/2023100 units assessed CPE via BPS-approved PDP
20171/1/201812/31/2024100 units assessed CPE via BPS-approved PDP
20181/1/201912/31/2025100 units assessed CPE via BPS-approved PDP
20191/1/202012/31/2026100 units assessed CPE via BPS-approved PDP
20201/1/202112/31/2027100 units assessed CPE via BPS-approved PDP
20211/1/202212/31/2028100 units assessed CPE via BPS-approved PDP
20221/1/202312/31/2029100 units assessed CPE via BPS-approved PDP
20231/1/202412/31/2030100 units (80 units assessed CPE via BPS-approved PDP + 20 units CPD)
2024 onward1/1/2025 onward12/31/2031 onward100 units (80 units assessed CPE via BPS-approved PDP + 20 units CPD)

At the time of recertification, the BCNP is also required to certify that they are not currently under suspension by either the U.S. Nuclear Regulatory Commission or a State Radiation Control Organization. All candidates for recertification must have a current active license/registration to practice pharmacy. 

For full details regarding recertification, please refer to the BPS Recertification Guide.

Board-Certified Infectious Diseases Pharmacists® are required to pay the BPS Annual Certification Maintenance fee of $125 each year for years one through six and the $400 recertification fee in year seven. Individuals with more than one BPS certification are assessed one BPS Annual Certification Maintenance Fee each year. 

Upcoming Deadlines

Candidates are required to recertify every 7 years. Certificants must submit their recertification application no later than the deadline of August 4. BPS encourages candidates to submit their recertification application as early as January 1 of their recertification year.

Candidates who intend to recertify via examination should note the availability of the recertification examination and related application deadlines. Candidates recertifying their BCNP credential by examination can find more information about examination dates and fees here

Candidates who intend to recertify via continuing education (CE) MUST submit their recertification application by the deadline date of August 4 even if they have not completed their CE requirements.

The deadline to complete the required CE for recertification is December 31 for all specialties. The board-certified pharmacist is responsible for submitting an application that is completely and accurately filled out. Incomplete and/or unpaid applications will not be processed.

Recertification Guide

The recertification guide is intended to provide BPS-certified pharmacists with information on the recertification process. To review recertification information, visit this page.

CPE Providers

BCNP with certification beginning January 1, 2023 or earlier: recertification via professional development program requires 100 units of assessed CPE from BPS-approved professional development programs provided by:

 

BCNP with certification beginning January 1, 2024 or later: recertification via professional development program requires 100 units, comprised of 80 units of assessed CPE from BPS-approved professional development programs provided by:

Additionally, 20 units of continuing professional development (CPD) must be completed and self-reported in MyBPS. For more information on CPD, review the FAQ. To maintain an active certification in good standing, a minimum of two units of assessed CPE from BPS-approved professional development programs or self-reported CPD must be reported each year.

Content Outline for BCNP

For the 2024 Examinations and forward, refer to the Nuclear Pharmacy Content Outline found here for details.

Please note that the Nuclear Pharmacy Specialty Certification and Recertification examinations transitioned to continuous testing starting in 2023. To learn more about the transition to continuous testing, click here

The examination content outline is a product of a job analysis, also known as a role delineation study, that includes discussions with a panel of 15-20 subject matter experts who represent the specialty area. These experts determine the competencies required for safe and effective pharmacy practice in the specialty area and engage board-certified pharmacists through a validation survey for their endorsement of the identified competencies. The job analysis process is conducted every 5 years to help ensure that the competencies in the examination content outline reflect current pharmacy practice in the specialty area.

Click here to review the BCNP Job Analysis Summary.

Important Resources

Apply for ADA Accomodations 

BPS complies with the relevant provisions of the Americans with Disabilities Act (ADA). For applicants looking to request special accommodations in their application process, more instructions can be found on this page.

Frequently Asked Questions

After review of the BPS Recertification Guide, some applicants may still have questions. Visit this page to see frequently asked questions from pharmacists renewing their board certification like you!

Sample Examination Items

Sample Items for BCNP Examinations

The sample examination items for BCNP examinations are made available by BPS for the purposes of familiarizing certification candidates and other stakeholders with the structure and format of BPS certification examinations. This is not meant for use as a self-assessment. Performance on any of these items does not correlate with performance on the actual examination.

The content of these examples is meant to be illustrative of actual examination items, but these items do not appear on the certification examination and are not meant to identify the scope of the examination. For a more comprehensive indication of the scope of the recertification examination, please refer to the BCNP Exam Content Outline.

Examination items are in multiple-choice format. The great majority of examination items are multiple-choice with a single response from among four options. Some examinations may include a small percentage of items that require selection of multiple (three or four) responses from among a larger set of available (up to eight) options. Examinations items may also be supplemented by an image.

View the examination items down below.

What is the primary radionuclidic impurity in yttrium Y–90?

Indium In–113
Strontium Sr–89
Strontium Sr–90
Thallium Tl–203

Correct!

Incorrect!

Which reagent kits is light-sensitive?

Mertiatide
Exametazime
Sestamibi
Medronate

Correct!

Incorrect!

What is an appropriate therapy for Graves disease?

10 - 15 mCi sodium iodide I-123
5 - 10 mCi sodium iodide I-131
0.5 - 1.0 mCi iodine I-131 iobenguane sulfate
75 - 150 mCi sodium iodide I-131

Correct!

Incorrect!

Dosage of yttrium Y-90 ibritumomab tiuxetan is based on:

body weight and platelet count.
body weight, platelet count, and sensitivity to murine proteins.
platelet count and biodistribution of iodine I–125 ibritumomab tiuxetan.
body surface area.

Correct!

Incorrect!

For which one of the following technetium-labeled radiopharmaceuticals may the biological distribution be altered by the presence of excessive concentrations of aluminum ion?

Pentetate
Gluceptate
Macroaggregated albumin
Sulfur colloid

Correct!

Incorrect!

If a technetium Tc-99m albumin aggregated kit containing 4 million particles was reconstituted at 6:00 AM using 50 mCi of technetium Tc-99m sodium pertechnetate, what is the earliest time at which a 4-mCi dosage would include more particles than the recommended limit of 700,000?

9:00 AM
11:00 AM
1:00 PM
3:00 PM

Correct!

Incorrect!

Which represents the activity of 20 mCi?

7.4 MBq
74 MBq
740 MBq
7.4 GBq

Correct!

Incorrect!

According to the USP, what is the maximum allowable aluminum-ion concentration in technetium Tc-99m pertechnetate solution prepared from molybdenum Mo-99 generators?

10 µg/mL
10 mg/mL
10 µg/mCi
10 mg/mCi

Correct!

Incorrect!

What is the regulatory maximum limit for Mo-99 breakthrough in any generator elution at time of administration?

1.5 µCi Mo-99 / mCi of Tc-99m
0.15 mCi Mo-99 / mCi of Tc-99m
0.15 µCi Mo-99 / mCi of Tc-99m
5 µCi per dose of Tc-99m

Correct!

Incorrect!

At what distance in centimeters would a source read 2 mR/hr if at 2 cm the radiation intensity is 500 mR/hr?
22.3
31.6
44.7
125.0

Correct!

Incorrect!

The gross mass of a radioactive package must be durably marked if it weighs more than:

55 lbs.
110 lbs.
155 lbs.
200 lbs.

Correct!

Incorrect!

What is the most likely cause of focal radioactivity in the lungs following administration of radiolabeled white blood cells?

Introduction of product through an existing central venous hyperalimentation line
Withdrawal of blood into the syringe prior to the injection
Normal distribution of the labeled leukocytes
Reinjection of cellular clumps

Correct!

Incorrect!

The use of technetium Tc-99m albumin aggregated injection is contraindicated in patients with:
shunt imaging.
severe pulmonary hypertension.
chronic obstructive pulmonary disease.
one lung.

Correct!

Incorrect!

The dosage of technetium Tc-99m disofenin given to a patient with an elevated total serum bilirubin level should be:
the same as for a patient with a normal serum bilirubin.
higher than the dosage given to a patient with a normal serum bilirubin.
contraindicated in patients with an elevated bilirubin level.
lower than the dosage given to a patient with a normal serum bilirubin.

Correct!

Incorrect!

What is the most critical time for precautions for urinary contamination after strontium chloride Sr-89 administration?
First 2 days
First week
First month
First 3 months

Correct!

Incorrect!

Share the quiz to show your results !

Subscribe to see your results

Nuclear Pharmacy Sample Questions

I got %%score%% of %%total%% right

%%description%%

%%description%%

Loading...

Certification Verification

BPS offers the ability to search and verify a Board-Certified Pharmacist by name or credential number.